The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes. While supply chain interruptions ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Ferring Pharmaceuticals announced strong performance results for 2024, with one part of the announcement standing out as ...

As the tariff situation continues to unfold in unexpected ways, the pharma industry must prepare for multiple eventualities.

The submission is backed by clinical data from over 2,100 patients, including two pivotal Phase III trials in patients ...

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

Pooja Lal, VP of strategy and commercial content at Veeva Systems, spoke with Pharmaceutical Executive about some of the ways ...

Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

Arda Ural discusses the different ways that companies may change the ways they allocate resources in the current geopolitical climate.

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...